# Metformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization

**Authors:** Ping Nie, Bo Yao, Zhejun Zhang, Jingling Li, Minghua Wang, Gendie E. Lash, Bihui Guo, Ping Li

PMC · DOI: 10.1186/s12967-025-07294-5 · Journal of Translational Medicine · 2025-11-12

## TL;DR

Metformin helps protect the ovaries from chemotherapy damage by altering immune cell interactions and reducing fibrosis.

## Contribution

The study reveals a new mechanism where metformin targets the MIF/CD74 pathway to reduce ovarian fibrosis.

## Key findings

- Metformin suppresses the MIF/CD74 signaling pathway activated by cyclophosphamide in ovarian tissues.
- Metformin reverses macrophage polarization imbalance and reduces fibroblast activation and ECM production.
- CD74 knockdown in fibroblasts inhibits fibrotic responses, while CD74 overexpression worsens them.

## Abstract

Cyclophosphamide (CTX) -induced ovarian fibrosis is involved in premature ovarian failure (POF). While metformin has demonstrated anti-fibrotic properties, the mechanism by which it regulates fibroblast activation, the primary effector cells in fibrosis, remains unclear in POF.

The therapeutic effects of metformin were investigated in CTX-treated mice and further explored its interaction with macrophage-fibroblast crosstalk using an in vitro co-culture system.

RNA sequencing revealed that metformin suppressed the MIF/CD74 signaling pathway, which was significantly activated by CTX in ovarian tissues. In vitro, CTX increased the CD86+/CD206 + macrophage ratio via NF-κB pathway activation, indicating altered macrophage polarization. Metformin or the MIF inhibitor ISO-1 reversed this polarization imbalance, thereby attenuating fibroblast activation and extracellular matrix (ECM) production in co-culture models. Additionally, CD74 knockdown in fibroblasts downregulated ECM-related genes and inhibited MAPK/JNK signaling, whereas CD74 overexpression exacerbated the fibrotic responses.

These findings highlight a novel mechanism by which metformin alleviates CTX-induced ovarian fibrosis by targeting the MIF/CD74 axis to reprogram macrophage-fibroblast communication, suggesting metformin as a protective adjuvant to improve ovarian health during chemotherapy.

The online version contains supplementary material available at 10.1186/s12967-025-07294-5.

## Linked entities

- **Genes:** MIF (macrophage migration inhibitory factor) [NCBI Gene 4282], CD74 (CD74 molecule) [NCBI Gene 972], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** metformin (PubChem CID 4091), cyclophosphamide (PubChem CID 2907), ISO-1 (PubChem CID 4633677)
- **Diseases:** premature ovarian failure (MONDO:0001119)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mif (macrophage migration inhibitory factor (glycosylation-inhibiting factor)) [NCBI Gene 17319] {aka DER6, GIF, Glif}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Cd74 (CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)) [NCBI Gene 16149] {aka CLIP, DHLAG, HLADG, Ia-GAMMA, Ii}
- **Diseases:** ovarian fibrosis (MESH:D010049), POF (MESH:D016649), fibrosis (MESH:D005355), CTX (MESH:D019294)
- **Chemicals:** CTX (MESH:D003520), ISO-1 (-), Metformin (MESH:D008687)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12613643/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12613643/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12613643/full.md

---
Source: https://tomesphere.com/paper/PMC12613643